July 9 (Reuters) - Albireo Pharma Inc ::ALBIREO PROVIDES MID-YEAR CLINICAL DEVELOPMENT UPDATE.ALBIREO PHARMA INC - EXPECTS ODEVIXIBAT PEDFIC 1 PHASE 3 TOPLINE DATA MID-2020 -.ALBIREO PHARMA INC - SITE ACTIVATED FOR ODEVIXIBAT PEDFIC 2 EXPANDED OPEN-LABEL COHORT.ALBIREO PHARMA INC - ODEVIXIBAT BILIARY ATRESIA PIVOTAL TRIAL EXPECTED TO BEGIN IN 2020.ALBIREO PHARMA INC - MOVES INTO NASH WITH INITIATION OF ELOBIXIBAT PHASE 2 TRIAL.ALBIREO PHARMA INC - ENCOURAGED WITH RECRUITING EFFORTS BY PARTICIPATING SITES IN OUR PHASE 3 TRIAL FOR ODEVIXIBAT IN PFIC.
Full Article
March 7 (Reuters) - Albireo Pharma Inc ::ALBIREO REPORTS YEAR-END 2018 FINANCIAL RESULTS AND PROVIDES PIPELINE UPDATE.ALBIREO PHARMA INC - A4250 PHASE 3 PFIC PIVOTAL PROGRAM ON TARGET FOR END OF '19/EARLY '20 TOPLINE READOUT.ALBIREO PHARMA INC - HAD CASH AND CASH EQUIVALENTS AT DECEMBER 31, 2018 OF $163.9 MILLION, COMPARED TO $53.2 MILLION AT DECEMBER 31, 2017..ALBIREO PHARMA INC - FOR FULL YEAR 2019, ANTICIPATE TOTAL EXPENSES, INCLUDING RESEARCH AND DEVELOPMENT AND G&A EXPENSES, TO BE IN RANGE OF $75-$80 MILLION.ALBIREO PHARMA INC - EXPECT CURRENT CASH BALANCE TO BE SUFFICIENT TO MEET OUR OPERATING NEEDS INTO 2021..
Full Article
March 6 (Reuters) - Albireo Pharma Inc ::ALBIREO PHARMA INC FILES FOR MIXED SHELF OF UP TO $200 MILLION – SEC FILING.
Full Article
Dec 18 (Reuters) - Albireo Pharma Inc ::ALBIREO GRANTED ORPHAN DESIGNATION BY EUROPEAN COMMISSION FOR LEAD PRODUCT CANDIDATE A4250 FOR TREATMENT OF BILIARY ATRESIA.ALBIREO PHARMA - PLAN TO EXPAND DEVELOPMENT OF A4250 IN RARE CHOLESTATIC LIVER DISEASES IN 2019.ALBIREO PHARMA - ORPHAN DESIGNATION PROVIDES 10 YEARS MARKET EXCLUSIVITY UPON APPROVAL PLUS 2 YEARS UPON COMPLETION OF PEDIATRIC INVESTIGATION PLAN.
Full Article
Nov 13 (Reuters) - Albireo Pharma Inc ::ALBIREO REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS.Q3 LOSS PER SHARE $1.17.Q3 REVENUE $237,000.Q3 REVENUE VIEW $892,000 -- THOMSON REUTERS I/B/E/S.Q3 EARNINGS PER SHARE VIEW $-0.98 -- THOMSON REUTERS I/B/E/S.ODEVIXIBAT SELECTED AS INTERNATIONAL NONPROPRIETARY NAME (INN) FOR A4250.A4250 GRANTED FAST TRACK AND ADDITIONAL ORPHAN DRUG DESIGNATIONS.A4250 PHASE 3 TRIAL PROGRESSING AS PLANNED, NEW NATURAL HISTORY DATA PRESENTED AT AASLD.ALBIREO PHARMA - HAD CASH AND CASH EQUIVALENTS AT SEPT 30, 2018 OF $173.6 MILLION, COMPARED TO $53.2 MILLION AT DEC 31, 2017.ALBIREO PHARMA - EXPECT CURRENT CASH BALANCE TO BE SUFFICIENT TO MEET OPERATING NEEDS INTO 2021.ALBIREO PHARMA - FOR FY 2018, ANTICIPATE TOTAL EXPENSES, INCLUDING RESEARCH AND DEVELOPMENT AND G&A EXPENSES, TO BE AT HIGH END OF RANGE OF $45 MILLION -$50 MILLION.
Full Article
Earnings vs. 
Estimates